Genprex Q3 10-Q: Going Concern Reiterated Despite $15.3M Cash After $18.7M ATM Raise
GNPX sits 22% above its 52-week low of $1.71.
Summary
Genprex's Q3 10-Q shows $15.3 million of cash after $18.7 million of ATM sales, but the company repeats going concern doubt and unremediated material weaknesses while its nine-month loss widened to $13.1 million.
Key Events · Earnings and Guidance · GNPX
-
Cash Rises to $15.3M on ATM Sales
Cash and cash equivalents reached $15,347,276 at September 30, 2026, up from $7,830,855 at December 31, 2025, after 993,436 shares sold under the 2023 ATM Facility for $18.73 million net in the nine months.
-
Nine-Month Loss Widens to $13.1M
Net loss was $13,145,839 versus $12,438,742 a year earlier; R&D rose 13% to $8,172,585 and G&A rose 7% to $5,076,482.
-
Going Concern Doubt Reiterated
Management states substantial doubt about the ability to continue as a going concern, with no revenue source and a $184,174,235 accumulated deficit, though cash is expected to fund operations into the second half of 2027.
-
Material Weaknesses Remain Unremediated
Disclosure controls were not effective at September 30, 2026 due to material weaknesses in segregation of duties and insufficient in-house accounting depth; remediation is underway but not yet demonstrated.
Analysis · GNPX · Life Sciences
Cash stood at $15.3 million at September 30, up from $7.8 million at year-end, after Genprex sold 993,436 shares through its ATM for $18.73 million net in the first nine months. That money buys time — management says it funds operations into the second half of 2027 — but the company still carries a $184.2 million accumulated deficit, has no revenue, and repeats the substantial doubt about its ability to continue as a going concern. The nine-month net loss widened to $13.1 million from $12.4 million as R&D and G&A both climbed. Material weaknesses in internal controls (segregation of duties, thin accounting staff) remain unremediated. The cash cushion is real, but it was bought with heavy share issuance and the underlying survival question is unchanged.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNPX was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $1.71 to $103.16. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.